Drug Approval | February 21, 2025
USFDA issues Form-483 for Piramal Pharma's facility at Turbhe
Observations are largely around improvement of procedures and practices
Observations are largely around improvement of procedures and practices
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
The Alathur facility specializes in the production of Cephalosporin antibiotics
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
He has over 23 years of experience across sectors
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Subscribe To Our Newsletter & Stay Updated
